1. Gohari MR, Mokhtari Hesari P, Moghaddami Fard Z, Khodabakhshi R. Determining pattern of metastasis and prognostic factors in breast cancer using conditional regression model (PWP). Scientific Journal of School of Public Health and Institute of Public Health Research. 2014; 12(1): 41-51.
2. Colon E, Rayer JS, Gonzalez Keelan C, Climent peris C. Prevalence of steroied Receptor and Her-2/Neu in Breast biopsies of women living in puertorico. Journal of Puertorice health-sciences. 2002; 21(4): 299-303.
3. Sharif Sistani N, Sadeghian M. H, Homaei F, Haghighati F. Immunohistochemical Study of cell proliferation marker,estrogen and progesterone receptors in breast carcinoma. Birjand Univ med Sci 2006; 13(3): 38-45.
4. Naghshvar F, Torabizadeh Zh, EmadianO, Zare A,Ghahremani M. Status of estrogene, progesterone receptors and HER-2/neu expression in invasive breast cancer. Gorgan University Medical Science. 2007; 8(4): 64-67.
5. Li MH, Hou CL, Wang C, Sun AJ. HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women. Pathol Res Pract. 2016; 212(4):
252-257.
6. Sheikhpour, R., & Mohiti Ardekani, J. The effect of progesterone on p53 protein in T47D cell line. Urmia Medical Journal. 2014; 25(10): 954-960.
7. Hashemi M, Ghavami S. Effects of estradiol, progesterone and testosterone on proliferation of human breast cancer cell lines. Zahedan university of Medicalscience and Health Services. 2005; 7(1):
21-29.
8. Mirzaei HR, Sabahat A, Nasrollahi F,
Mohammadi-Yeganeh L. Correlation between ER, PR, HER2 receptors and prognostic factors in breast cancer. Pejouhandeh 2010; 15(4): 152-156.
9. Moradi Marjaneh M, Homaei Shandiz F, Shamsian A, Eftekharzadeh Mashhadi I, Hedayati Moghaddam M.R, Bidkhori H.R, Ghafarzadegan K. Prognostic role of her2/new, P53, ER and PR in Breast Cancer: First report from northeast of iran. 2008; 2(1): 7-17.
10. Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen
Receptor-Positive and HER2-Negative Breast Cancer. Clinical Breast Cancer 2014.
11. Shakeri M, Ghavami Ghanbarabadi V, Esmaeili H, Gabbari Noghabi H, Homaei Shandiz F, Baghishani H. Analysis of survival data of patients with breast cancer with Cox proportional hazards model for dependent censoring based on copula function. Journal of North Khorasan University of Medical Sciences.2011; 3: 53-64.
12. Saunders Ch, Jassal, S. Breast cancer. Oxford University Press. 2009; (1. ed.). Chapter 13.
13. Alizadeh SA, Moshfeghi K, Kalantari M,Ebrahimi Kh. Lymph -node involvement and tumor markers in patients with breast cancer. Arak Medical University Journal. 2010; 12(4): 44-50.
14. Endo A, Shibata T, Tanaka H. Comparison of seven algorithms to predict breast cancer survival. Survival. 2008; 30: 11-16.
15. Abdolmaleki P, Yarmohammadi M, Gity M. Comparison of logistic regression and neural network models in predictin the outcome of biopsy in breast cancer from MRI findings. Iranian Journal of Radiation Research.2004; 1: 217-228.
16. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K. Hormone receptors as prognostic factors in female breast cancer. Annals of Medicine 1991; 23(6): 643-648.
17. Biesterfeld S, Klüppel D, Koch R, Schneider S, Steinhagen G, Mihalcea AM, Schröder W. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistochemistry of the most positive tumor focus. Journal of Pathology. 1998; 185: 25.
